Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse. After a positive pilot study, the authors tested the α-1 adrenergic receptor antagonist prazosin to treat alcohol use disorder in a larger sample. METHOD: Ninety-two participants with alcohol use disorder but without posttraumatic stress disorder were randomly assigned to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2. The behavioral platform was medical management. Participants provided daily data on alcohol consumption. Generalized linear mixed-effects models were used to examine the impact of prazosin compared with placebo on number of drinks per week, number of drinking days per week, and number of heavy drinking days per week. RESULTS: Eighty participants completed the titration period and were included in the primary analyses. There was a significant interaction between condition and week for both number of drinks and number of heavy drinking days, such that the rate of drinking and the probability of heavy drinking showed a greater decrease over time for participants in the prazosin condition compared with those in the placebo condition. Participants in the prazosin condition were more likely to report drowsiness and edema than participants in the placebo condition. CONCLUSIONS: Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random effects structure for confirmatory hypothesis testing: Keep it maximal
Barr, D. J., Levy, R., Scheepers, C., & Tily, H. J. (2013) · Journal of Memory and Language · doi:10.1016/j.jml.2012.11.001 · Cited by 10,328 · cited 2×
“potential for fixed-slope models to have an inflated type I error (26, 27); and 4) using only the last week for which daily data were reported and analyzing those data with generalized linear models that included a term for condition and the covariates of sex, age, veteran status, and baseline average number of drinks…”
BackgroundMethodConclusions beyond support: overconfident estimates in mixed models
Schielzeth, H., & Forstmeier, W. (2009) · Behavioral Ecology · doi:10.1093/beheco/arn145 · Cited by 952
Brain stress systems in the amygdala and addiction
Koob, G. F. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.038 · Cited by 388 · cited 1×
“Evidence suggests that elevated brain noradrenergic activity appears to be involved in the initiation and maintenance of alcohol use disorder (1, 2).”
Background
Cited by
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“More recently, 92 participants with AUD completed a 12-week double-blind study with prazosin and medication management [207].”
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“New treatment strategies such as controlled drinking, which overturns thewidespread dogmaof abstinence, also deserve to be considered (Simpson et al., 2018; Henssler et al., 2021; Paquette et al., 2022).”
BackgroundA 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195539 · Cited by 28
Vanderkam, P., Solinas, M., Ingrand, I., Doux, N., Ebrahimighavam, S., Jaafari, N., & Lafay‐Chebassier, C. (2021) · Addiction · doi:10.1111/add.15265 · Cited by 25
Metadata
- Authors
- Simpson, T. L., Saxon, A. J., Stappenbeck, C., Malte, C. A., Lyons, R., Tell, D., Millard, S. P., & Raskind, M.
- Venue
- American Journal of Psychiatry
- Published
- 2018-12-01
- Volume
- 175
- Issue
- 12
- Pages
- 1216-1224
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2889479634
- Cited by
- 76
- References
- 3
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.